COMPANY NEWS
Admission of Product to the PRC National Drug List for Reimbursement, Beifuxin Newly Listed and the Other Three Products Remain on the List
2019.08.21
Download
Hong Kong, 21 August 2019
Essex Bio-Technology Limited (“EssexBio” or the “Group”, Stock code: 1061) today is pleased to announce that Recombinant Bovine Basic Fibroblast Growth Factor (rb-bFGF) Gel (Product series: Beifuxin) has been newly admitted to the latest National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (“NDL”) issued by National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the People’s Republic of China on 20 August 2019, whilst the other three bio-pharmaceutical products that were previously included in 2017 NDL remain to be listed.
Details of the Group’s listed bio-pharmaceutical products are set out below:
Essex Bio-Technology Limited (“EssexBio” or the “Group”, Stock code: 1061) today is pleased to announce that Recombinant Bovine Basic Fibroblast Growth Factor (rb-bFGF) Gel (Product series: Beifuxin) has been newly admitted to the latest National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (“NDL”) issued by National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the People’s Republic of China on 20 August 2019, whilst the other three bio-pharmaceutical products that were previously included in 2017 NDL remain to be listed.
Details of the Group’s listed bio-pharmaceutical products are set out below:
| Product series | Product form | Common name | Status |
| Beifushu | Eye Drops | recombinant bovine basic fibroblast growth factor (rb-bFGF) |
Class B (No. 444) |
| Beifushu | Eye Gel | recombinant bovine basic fibroblast growth factor (rb-bFGF) |
Class B (No. 444) |
| Beifuji | Lyophilized Powder | recombinant bovine basic fibroblast growth factor (rb-bFGF) |
Class B (No. 447) |
| Beifuxin | Gel | recombinant bovine basic fibroblast growth factor (rb-bFGF) |
Class B (No. 447) |
The Board of Directors believe that the inclusion of Beifuxin, the largest turnover contributor of the Company, into NDL will further accelerate the expansion of distribution network of the Group’s flagship bio-pharmaceutical products in PRC and provide a strong impetus for organic growth in the immediate future.
Related news
Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%
2024-03-18
Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%
2023-08-16
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
2023-07-26
Essex Bio-Technology Announces 2022 Annual Financial Results, Resilience & Relevance, Growth Ready
2023-03-08
Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)
2021-10-27
Application for Clinical Trial of Bevacizumab Has Been Approved for the Treatment of wAMD in Latvia
2021-04-20
Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia
2021-01-29
Essex Bio-Technology and Antikor Biopharma Forge Strategic Alliance in FDC for Cancer Treatment
2019-08-02
粵公網安備 44049102496184號